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An 11- year- old boy arrived at the emergency room with 
 hemoptysis after waking up with dry cough. The child’s clin-
ical history revealed two other episodes of blood after cough-
ing; in those cases, an otorhinolaryngologist examination was 
performed, with negative rhinoscopy. No past acute infectious 
disease, no impaired hemostasis, no intake of drugs or recent 
trauma. At the clinical examination in Emergency room, the 
child appeared pale and painful with respiratory rate 40 acts 
per minute and hypophonesis at pulmonary apex. Heart rate 
is 90 beats per minute with normal electrocardiogram (ECG) 
and QTC values, sinus rhythm, 96% oxygen saturation. Blood 
tests: GB 4.48 × 10^9/L, VES 32 m/h, Hb 11.6 g/L. At X- 
ray evidence of epigraphic formation 8 × 5 cm at left lung 
(Figure 1). The chest CT scan confirmed an 8 cm diameter 
“massive inhomogeneous solid formation” in proximity to 
the left pulmonary upper lobe, which improved after contrast 
medium. Specifically, ground- glass opacity image indicates 
thickening at the middle and at the level of the lingula and 
seemed to be infiltrating pulmonary arteries, making the 
prognosis inoperable (Figure 2).
The child was admitted to the pediatric unit, and a tho-
racic surgical consultation was requested. The following step 
was the bronchoscopy, which did not reveal pathological 
characteristics. Taking into account the stable general condi-
tion, the absence of a severe anemia as well as the presence 
of normal values of the vital parameters, the patient under-
went intravenous tranexamic acid therapy and was decided 
not to perform an urgent and hazardous surgical procedure, 
choosing waiting and seeing behavior. The day after, a new 
massive hemoptysis with hematemesis with spontaneous 
resolution accelerated diagnostic workup: an angio CT scan 
was performed and revealed that the tumor did not infiltrated 
pulmonary arteries, but bronchial ones, so that the progno-
sis suddenly changed. An extemporary biopsy of the lesion 
showed the presence of inflammatory cells; consequently, 
in the suspect of an infectious pathogenesis, the child was 
treated with antibiotics (piperacillin/tazobactam) and anti-
fungal drugs. The definitive histologic diagnosis confirmed 
the presence of inflammatory cells, and the mass was re-
vealed to be an inflammatory myofibroblastic lung tumor 
and not just an infection. The child underwent a lobectomy 
of left pulmonary upper lobe with a good follow- up at X- rays 
and blood tests.
This article reports the pediatric case of inflammatory my-
ofibroblastic tumor, a rare benign tumor localized in the left 
lung, composed of spindle cell fibroblast and myofibroblast 
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The diagnosis of inflammatory myofibroblastic tumor is based on radiology and 
 histology. The treatment is surgical, and the prognosis is good. For this reason, al-
though this lung disease is rare, when a child show up at hospital with an unknown 
hemoptysis, this medical condition should not be underestimated.
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proliferation with plasma cells, lymphocytes, and histio-
cytes.1 This benign tumor was detected after an episode of 
moderate hemoptysis.2 Due to the uncommon onset, it was 
challenging to establish the accurate diagnosis.
The term “hemoptysis” is referred to the expectoration of 
blood or the presence of blood in the sputum.2 The bleeding 
can arise from both pulmonary arterial circulation and bron-
chial circulation. Understanding the dimension of the bleed-
ing is essential because it changes the diagnostic workup3.
Specifically, bleeding can be “scant” (<5 mL), “mild to 
moderate” (6–240 mL), or “massive” (more than 240 mL).4 
In children, principal causes of hemoptysis are as follows: 
respiratory infection, aspiration of foreign bodies, and bron-
chiectasis. However, hemoptysis can be rarely caused by 
vasculitis and associated syndromes, congenital heart dis-
ease and cardiac- related conditions, congenital lung malfor-
mations, pulmonary vascular disorders, pulmonary masses, 
trauma, idiopathic, coagulopathy and thrombosis, toxic in-
halation, bone marrow transplant, pulmonary veno- occlusive 
disease, celiac disease, connective tissue disorders (Ehlers 
Danlos syndrome and Loeys Dietz syndrome), plasma cell 
granuloma, and catamenial hemoptysis (females).5
The management of the different cases of massive, mod-
erate, and scant hemoptysis varies according to the condition. 
Massive hemoptysis represents a life- threatening condition 
that warrants urgent treatment. At first, the patient needs to 
be stabilized in order to prevent further bleeding. After the 
stabilization of the patient, the evaluation of the cause of the 
hemoptysis can be carried out.
Mild hemoptysis and moderate hemoptysis are more fre-
quent and do not represent a medical emergency; in fact, they 
tend to resolve spontaneously. Their management should be ori-
ented on the basis of an accurate history, focusing the attention 
on the presence of known underlying disease, physical exam-
ination, laboratory tests, such as complete blood count and co-
agulation study, and chest radiograph. Starting from these four 
steps, it is often possible to understand if the cause of hemopty-
sis has good prognosis and does not require further intervention 
or if it represents a pathologic condition, which requires a spe-
cial medical attention. In this last case, it is necessary to perform 
other investigations, such as bronchoscopy, CT of the lung and 
eventually lung biopsy. Guidelines recommend to suspend chest 
physiotherapy, to avoid noninvasive ventilation, and to evaluate 
the possibility of sedation and cough suppression drugs,4,6 until 
the cause of the hemoptysis is identified.
Inflammatory myofibroblastic lung tumor belongs to 
the category of primary neoplasm of the lung1 and has a 
prevalence of 0,7%,7 but, among these types of tumors, of 
about 25%. Inflammatory myofibroblastic tumor of the 
lung is made up by spindle cell fibroblast, myofibroblast 
proliferation with a mixture of plasma cells, lymphocytes, 
and histiocytes.1 The major part arises from the lung; only 
12% can arise from the bronchi. Pediatric patients are often 
asymptomatic, and symptoms such as cough, fever, short-
ness of breath, and hemoptysis are usually rare.1 For what 
concerns instrumental diagnosis, the first step is chest radi-
ography: specifically, inflammatory myofibroblastic tumor 
appears as a solitary pulmonary mass; rarely, atelectasis and 
pleural effusion are present.1 Calcifications are common in 
pediatric patients, too.1 In 5% of the cases, masses are multi-
ple.1 The second instrumental step is CT scan: calcifications 
are more evident and can direct the diagnosis.1 MRI can be 
an alternative instrumental examination; in fact, inflamma-
tory myofibroblastic tumors typically have low intermediate 
T1 signal and high T2 signal.1 Another second instrumental 
step is fluorodeoxyglucose positron emission tomography: it 
can demonstrate inflammatory components.1
F I G U R E  1  (X- ray): Left pulmonary upper lobe occupied by oval 
expansive formation of 8 × 5 cm
F I G U R E  2  (Chest CT Scan): Massive inhomogeneous solid 
formation (inner diameter 8 cm) in proximity to the left pulmonary 
upper lobe, which improved after contrast medium
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The treatment of inflammatory myofibroblastic tumor is 
surgical.1 Surgery can define diagnosis of this type of tumor 
through the biopsy; specifically, only histological and immu-
nohistochemical studies can confirm the diagnosis.1
Chemotherapeutic agents are not useful and do not change 
the prognosis.8
In fact, if the resection of myofibroblastic lung tumor 
is complete, it is a good signal and there is low risk for 
recurrence.7
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